Literature DB >> 7622584

Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro.

M Guerrin1, H Moukadiri, P Chollet, F Moro, K Dutt, F Malecaze, J Plouët.   

Abstract

Vasculotropin (VAS), also called vascular endothelial growth factor (VEGF) or vascular permeability factor, is a secreted growth factor whose target cell specificity has been reported as restricted to vascular endothelium. Its effects are mediated by at least two distinct membrane-spanning tyrosine kinase receptors, KDR and flt-1; the expression of which also seems restricted to vascular endothelium. We describe here that cultured human retinal pigment epithelial (HRPE) cells express both KDR and flt-1 receptors, bind VAS/VEGF on two high affinity sites (apparent Kd of 9 and 210 pM corresponding to 940 and 18,800 sites per cell) and proliferate or migrate upon recombinant VAS/VEGF addition. HRPE cells also express the mRNA corresponding to the 121 and 165 amino acid forms of VAS/VEGF. HRPE cells release in their own culture medium and store in their extracellular matrix self-mitogenic and chemoattractant factors indistinguishable from 121 and 165 VAS/VEGF isoforms. The autocrine role of VAS/VEGF was confirmed by the inhibition of these bioactivities by neutralizing specific anti-VAS/VEGF antibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622584     DOI: 10.1002/jcp.1041640219

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  21 in total

Review 1.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

2.  An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris.

Authors:  Magali Saint-Geniez; Tomoki Kurihara; Eiichi Sekiyama; Angel E Maldonado; Patricia A D'Amore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

3.  Fluorescein angiography, optical coherence tomography, and histopathologic findings in a VEGF(165) animal model of retinal angiogenesis.

Authors:  Luís A Arana; Anderson T Pinto; Gerald J Chader; Jose D Barbosa; Sabina Morales; Ana T Moreira; Mauricio Maia; Mark S Humayun
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-20       Impact factor: 3.117

4.  Effects of 15d-PGJ(2) on VEGF-induced angiogenic activities and expression of VEGF receptors in endothelial cells.

Authors:  Philip Funovics; Christine Brostjan; Anneliese Nigisch; Anna Fila; Anna Grochot; Katarzyna Mleczko; Halina Was; Guenter Weigel; Jozef Dulak; Alicja Jozkowicz
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-03-31       Impact factor: 3.072

5.  Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes.

Authors:  Y S Chen; S F Hackett; C L Schoenfeld; M A Vinores; S A Vinores; P A Campochiaro
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

6.  Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy.

Authors:  G Smith; D McLeod; D Foreman; M Boulton
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

7.  Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

Authors:  D F Stefanik; W K Fellows; L R Rizkalla; W M Rizkalla; P P Stefanik; A B Deleo; W C Welch
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

Review 8.  [(Side) effects of VEGF inhibition].

Authors:  F Ziemssen; K U Bartz-Schmidt; S Grisanti
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

9.  VEGF localisation in diabetic retinopathy.

Authors:  M Boulton; D Foreman; G Williams; D McLeod
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

10.  [Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells].

Authors:  M Kernt; U Welge-Lüssen; A Yu; A S Neubauer; A Kampik
Journal:  Ophthalmologe       Date:  2007-11       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.